Our team has originated or contributed to the discovery and development of a range of drug candidates that moved into clinical development for the following targets: an p53/mdm2 protein-protein interaction inhibitor, dual orexin receptor antagonist (DORAs), a FAS receptor stabilizer, an MTX1 antibody drug conjugate as well as an oral bendamustin anti-cancer drug.
Dr. Lutz Weber, Co-founder, 30 years of biotech leadership experience (Roche, Co-Founder of MorphoChem, NexusPharma, CellProtect, OntoChem, OntoChem IT Solutions, MolGenie). Strong drug discovery related IT and R&D expertise in new drug discovery related technologies, oncology and cardiovascular diseases. Author of >100 scientific publications and >30 patents. https://www.linkedin.com/in/lutzweber
Dr. Wolfgang Richter, Co-founder, has more than 30 years of experience in the biotech industry as a founder and in different key management positions of several life science companies, including Morphochem AG, R&D-Biopharmaceuticals GmbH and TUBE Pharmaceuticals GmbH. His areas of expertise are CMC, preclinical and formulation development, IP management, in- and out-licensing. Dr. Richter is an inventor or co-inventor of many issued patents.
Dr. Aleksei Krasnov is our VP IT Development
He was previously at OntoChem GmbH working to implement new artificial intelligence driven methods for the knowledge management of chemistry data.
Scientific advisory board
Prof. Dr. Hans-Joachim Böhm, former Head of Chemistry at F. Hoffmann – La Roche AG, Co-Founder and Managing Director of Novomol. Creator of the EDEN platform to discover safe & effective small molecule drug candidates.